SuperworthHarvard Bioscience profit margin HBIO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −11.9%
- Operating margin, 12 months
- −0.3%
- Net margin on a year earlier
- +52.8 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Harvard Bioscience kept −11.9% of its revenue as net profit, with an operating margin of −0.3% and a gross margin of 58.2%.
Five years earlier its net margin was −2.5%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −65.5% | −56.1% | 57.7% |
| FY2024 | −13.2% | −6.6% | 58.2% |
| FY2023 | −3.0% | 1.7% | 58.9% |
| FY2022 | −8.4% | −6.1% | 53.7% |
| FY2021 | −0.2% | 1.7% | 56.9% |
| FY2020 | −7.6% | 0.2% | 56.8% |
| FY2019 | −4.0% | 0.3% | 55.4% |
| FY2018 | −2.4% | 0.8% | 52.3% |
| FY2017 | −1.1% | −0.8% | 50.6% |
| FY2016 | −4.1% | −2.9% | 46.3% |
| FY2015 | −17.5% | −1.6% | 44.8% |
| FY2014 | 2.2% | 6.1% | 45.4% |
| FY2013 | −1.7% | 1.5% | 45.4% |
| FY2012 | 2.1% | 7.0% | 47.1% |
| FY2011 | 3.5% | 5.6% | 46.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −11.9% | +52.8 pts | −0.3% | |
| Q1 FY26 | −11.4% | +52.1 pts | −0.1% | |
| Q4 FY25 | −65.5% | −52.3 pts | −56.1% | |
| Q3 FY25 | −61.6% | −47.0 pts | −57.5% | |
| Q2 FY25 | −64.7% | −54.1 pts | −59.0% | |
| Q1 FY25 | −63.5% | −55.3 pts | −58.6% | |
| Q4 FY24 | −13.2% | −10.1 pts | −6.6% | |
| Q3 FY24 | −14.6% | −11.7 pts | −6.1% | |
| Q2 FY24 | −10.6% | −5.8 pts | −4.9% | |
| Q1 FY24 | −8.2% | −6.4 pts | −2.0% | |
| Q4 FY23 | −3.0% | +5.4 pts | 1.7% | |
| Q3 FY23 | −2.9% | +2.9 pts | 1.0% |
Against its peers
Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.
| Company | Profit margin |
|---|---|
| HBIOHarvard Bioscience | −11.9% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
Where Harvard Bioscience ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Harvard Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.